Navigation Links
Ceregene Phase 2 Clinical Trial for Alzheimer's Disease to be Funded by $5.4 Million Grant From National Institutes of Health
Date:11/4/2008

ved in Alzheimer's disease.

About Alzheimer's Disease

Alzheimer's disease is a progressive disorder of the brain that gradually affects one's memory and ability to learn, reason, communicate and carry out daily activities. There are now more than five million people in the United States living with Alzheimer's disease, and there is currently no cure.

About Ceregene

Ceregene, Inc. is a San Diego-based biotechnology company focused on the delivery of nervous system growth factors for the treatment of neurodegenerative disorders using gene delivery. Ceregene's clinical programs include CERE-110, an AAV2 based vector expressing nerve growth factor that is currently in Phase 1 studies for the treatment of Alzheimer's disease, and CERE-120 (AAV2-Neurturin) which has completed enrollment of a controlled Phase 2 study for Parkinson's disease. CERE-135 and CERE-140 are in preclinical development for ALS (Lou Gehrig's disease) and ocular disorders, respectively. Ceregene was launched in January 2001. The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell Genesys, Inc. (Nasdaq: CEGE) as well as Hamilton BioVentures and California Technology Partners.


'/>"/>
SOURCE Ceregene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinsons Disease
2. Derma Sciences Enrolls First Patient in DSC127 Phase II Study
3. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
4. Phase 2a Data for MEDI-528 Presented at CHEST 2008
5. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
6. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
7. QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
8. Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
9. Teksouth Awarded $100,000 Defense Department Grant in First Phase of Medical Data Integration Project
10. Assessing the quality of phase I clinical trial abstracts
11. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... published in the July, 2014, issue of the ... by Northwestern Medicine researchers, sheds new light on ... endoscopic resection in the treatment of localized, early-stage ... surgical resection, while more invasive, provided significantly better ... for patients than endoscopic resection, which had a ...
(Date:7/28/2014)... 2014 Mediaplanet announced distribution ... March 12th, a campaign that aims to raise awareness ... with industry leader TEALUX , a premium loose ... the campaign provides readers with educational insight about the ... propel the industry forward and make conscious organic choices ...
(Date:7/28/2014)... July 28, 2014 The Healthcare ... graduates of its Advanced Training Program in Healthcare ... roles in their health care organization ranging from ... methodology of continuous quality improvement in the health ... Dr. Brent James’ internationally recognized Advanced Training Program ...
(Date:7/28/2014)... have been forced to accept the diagnosis "growing pains" ... new PhD study involving 3,000 adolescents has now shown ... can see from the study that one in three ... experience problems with pain in their knees. Seven percent ... front of the knee," says physiotherapist and PhD Michael ...
(Date:7/28/2014)... Brea, CA (PRWEB) July 28, 2014 ... management business process outsourcing (BPO) for Fortune 500 brands, ... 2,500 jobs across its locations in Wisconsin, California, Florida ... will be based at its Brea campus. , A ... clients, which have seasonal ramp-ups that require additional staffing ...
Breaking Medicine News(10 mins):Health News:Study helps compare risks of treatments for early esophageal cancer 2Health News:Study helps compare risks of treatments for early esophageal cancer 3Health News:Mediaplanet's "Organic Living" Campaign Raises Awareness About What Nature Invented, With the Help of Partner TEALUX 2Health News:HORNE LLP’s Healthcare Delivery Institute Graduates Class from the Advanced Training Program 2Health News:Many people never grow out of their growing pains 2Health News:Alta Resources to Fill Approximately 700 Positions in Brea 2Health News:Alta Resources to Fill Approximately 700 Positions in Brea 3
... , ... the North Shore. , ... MA (Vocus) May 25, 2010 -- Blue Cross Blue Shield of Massachusetts, Inc. ... a five-year Alternative Quality Contract (AQC). The agreement marks the first North Shore ...
... Massachusetts Medical School report in the journal Nature Medicine ... malignant glioma, a pathway essential to the cancer,s ability ... that would stop the cancer,s ability to thrive. ... RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway ...
... But bad news is the prevalence of hypertension in U.S. ... While the number of Americans with high blood pressure has ... news is that more people with the condition have it ... is a major risk factor for heart attack, stroke and ...
... the the human intestinal tract may be associated with ... the University of Florida present their research today at ... Microbiology in San Diego, CA. "Our findings suggest ... subjects with polyps, early lesions that can develop into ...
... By layering dB-Bloc ... noise bleeding through a common surface. For new build or existing finished walls, discover ... ... noise from the next through a common wall or ceiling assembly is no longer an impossible ...
... as fast, researchers report , TUESDAY, May 25 (HealthDay News) ... research suggests bacteria could indeed, at least if you spend ... looked at mycobacterium vaccae , a kind of natural ... the germ when they spend time in nature, researcher Dorothy ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 2Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 3Health News:Blue Cross Blue Shield of Massachusetts and Northeast Health Systems Physician Hospital Organization Sign Alternative Quality Contract 4Health News:Novel RNA interference screening technique identifies possible path for malignant glioma treatment 2Health News:Report Finds Control of High Blood Pressure Improving 2Health News:Report Finds Control of High Blood Pressure Improving 3Health News:Share Your Walls, Not the Noise. Introducing dB-Bloc for Common Wall Sound Bleed 2Health News:Germs in Soil Might Give Learning a Boost 2
(Date:7/28/2014)... TOKYO , July 28, 2014  ImaginAb, ... Roger Crystal , MD as Vice President of ... Global Business Development Product Acquisition & Licensing team at ... developing business strategy and partnerships in the precision medicine ... partner with biotechnology and pharmaceutical companies across the spectrum ...
(Date:7/28/2014)... July 28, 2014   Cardioxyl Pharmaceuticals, Inc. ... demonstrating that CXL-1427, a novel potential treatment for acute ... volunteers. The company has now initiated dosing of hospitalized ... clinical trial designed to further evaluate the drug,s safety ... The Phase I clinical trial evaluated the safety ...
(Date:7/28/2014)... and NEW PROVIDENCE, N.J. , July ... are invited to meet with Linde,s Healthcare division ... to be held at McCormick Place in ... "Hospitals demand nothing less than complete confidence in ... , Linde,s Healthcare Segment manager. "Linde understands the importance ...
Breaking Medicine Technology:ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2
... Sept. 1 /PRNewswire-Asia-FirstCall/ -- ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... Insert From Carl Zeiss Meditec -- CLERMONT-FERRAND, France, September 1, 2010 ... ... lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so ...
Cached Medicine Technology:Yongye International Announces RMB 400 Million Revolving Credit Facilities 2Yongye International Announces RMB 400 Million Revolving Credit Facilities 3Yongye International Announces RMB 400 Million Revolving Credit Facilities 4Yongye International Announces RMB 400 Million Revolving Credit Facilities 5Yongye International Announces RMB 400 Million Revolving Credit Facilities 6Yongye International Announces RMB 400 Million Revolving Credit Facilities 7Yongye International Announces RMB 400 Million Revolving Credit Facilities 8French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 2French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 3French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 4French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 5French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 6French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec 7
... Anion traces: chloride (Cl) ≤ 500 mg/kg sulfate (SO ... 500 mg/kg Cd ≤ 5 mg/kg Co ≤ 5 ... Fe ≤ 10 mg/kg K ≤ 5 mg/kg Mg ... 2000 mg/kg Ni ≤ 5 mg/kg Pb ≤ 5 ...
Application: Capable of separating DNA fragments of 50 to 1000 bp on a 3% gel Solubility: water 15 mg/mL, clear, colorless, hot Special grade: for molecular biology Suitab tst: electrophoresis te...
Inquire...
Inquire...
Medicine Products: